Prostacyclin analog OP2507 prevents pulmonary arterial and airway constriction during lung preservation and reperfusion.
BACKGROUND
The effects of OP2507 on lung preservation with cold Euro-Collins solution and during the reperfusion period were evaluated.


METHODS
For this study, canine lungs were flushed with a 10 micrograms/ml OP2507 solution (n = 7) or saline solution (control group, n = 7) (0.1 ml/kg body weight) and stored in the same solution. Pulmonary arterial pressure, pulmonary vascular resistance, airway pressure, respiratory capacity, and wet to dry weight ratio of the lungs were measured before and after 24 hours of cold preservation and after a 60-minute reperfusion period.


RESULTS
Treatment with OP2507 significantly attenuated increases in pulmonary arterial pressure, pulmonary vascular resistance, and airway pressure after preservation and during the reperfusion period. Oxygen tension in outflow blood also was maintained with OP2507 treatment throughout the experimental period, whereas it was depressed during the reperfusion period in the control group. By electron microscopy, there was little evidence of vascular endothelial damage, such as cell swelling, detachment of endothelial cells from the lamina, and attenuation of the cytoplasm, in both groups. However, the tight junctions between cells were observed more clearly in the control group than in the OP2507 group, suggesting more cell membrane damage in the control group.


CONCLUSIONS
Pretreatment with OP2507 prevented pulmonary artery and airway constriction after 12 hours of cold lung preservation and a decrease of oxygen tension in outflow blood during a 60-minute reperfusion period.
Nawata
S
S
First Department of Surgery, Yamaguchi University School of Medicine, Japan.
Sugi
K
K
Ueda
K
K
Nawata
K
K
Kaneda
Y
Y
Esato
K
K
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002448:Cell Adhesion / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000648:ultrastructure; D003251:Constriction, Pathologic / Q000517:prevention & control; D015925:Cryopreservation; D003593:Cytoplasm / Q000187:drug effects / Q000648:ultrastructure; D004285:Dogs; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006982:Hypertonic Solutions / Q000627:therapeutic use; D016040:Lung Transplantation / Q000473:pathology; D008854:Microscopy, Electron; D009926:Organ Preservation; D009929:Organ Size; D010100:Oxygen / Q000097:blood; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011651:Pulmonary Artery / Q000187:drug effects*; D012123:Pulmonary Ventilation / Q000187:drug effects; D015424:Reperfusion; D019108:Tight Junctions / Q000187:drug effects / Q000648:ultrastructure; D014109:Total Lung Capacity / Q000187:drug effects; D014132:Trachea / Q000187:drug effects*; D014655:Vascular Resistance / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects
C037096:Euro-Collins' solution; D006982:Hypertonic Solutions; D010975:Platelet Aggregation Inhibitors; C049453:OP 2507; D011464:Epoprostenol; D010100:Oxygen